Dexamethasone intravitreal implant in the treatment of diabetic macular edema in the preoperative cataract setting: A case series

Poster Details

First Author: C.Arruabarrena SPAIN

Co Author(s):    J. Martinez                             

Abstract Details


To examine the efficacy of the dexamethasone (DEX) intravitreal implant (Ozurdex®; Allergan, Inc., Irvine, CA) in the control of diabetic macular edema in the preoperative setting of cataract surgery.


University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. It covers an area of 250 000 people.


Methods: Design: Retrospective observational case series. Participants: A total of 16 eyes of 13 patients that received a DEX implant for diabetic macular edema (CME) who underwent subsequent phacoemulsification within 4 months. Each patient was treated with a DEX 0.7 mg intravitreal implant and underwent phacoemulsification with intraocular lens placement. Primary outcome measure was the change in central macular thickness (CMT) measured by optical coherence tomography (OCT) measured preoperatively and one and 4 months postoperatively. Demographic data, previous treatments and BCVA were also recorded.


A total of sixteen eyes (13 patients) were included. Five of them were females. The preoperative CMT changed from a mean of 389.22 μm to a mean CMT 316.5 μm one month postoperative. There was no statistically significant change from preoperative macular volume (mean 8.92 μm) to postoperative macular volume (8.97 μm) on OCT.


Intravitreal dexamethasone implant was shown to prevent the recurrence or worsening of macular edema in diabetic patients with a history of DME who underwent phacoemulsification. The mean CMT decreased in the subset of eyes that received the DEX implant a mean of 72.72 μm, although OCT macular volume didn´t change significantly .

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy